Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.

Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.

http://www.wikidata.org/entity/Q34185893

about

Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.How I treat childhood CML.Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.Clinical review: kinase inhibitors: adverse effects related to the endocrine system.Neurotoxicity of biologically targeted agents in pediatric cancer trials Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia Targeting developmental pathways in children with cancer: what price success?Pediatric chronic myeloid leukemia is a unique disease that requires a different approach Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.Management of chronic myeloid leukemia in childhood.Is there a role for allogeneic transplantation in chronic myeloid leukemia?Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.Growth failure and nutrition considerations in chronic childhood wasting diseases.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.Treatment of chronic phase chronic myeloid leukemia with imatinib.Bone metabolism during long-term treatment with imatinib.Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia.Helping children with growth failure due to tyrosine kinase inhibitor drugs requires knowledge of the pathogenesis of the problem.Pharmacology and pharmacokinetics of imatinib in pediatric patients.Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.Adverse effects of imatinib in children with chronic myelogenous leukemia.Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy.Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia.Optimal management for pediatric chronic myeloid leukemia.Imatinib Inhibits GH Secretion From Somatotropinomas

P2860

Q28548625-FEE3A10F-7AEC-42C3-B197-F69F84C6AE7A Q30234441-D37475A2-4CDE-4AC1-813E-AB583590A416 Q35802202-A7E93A31-254D-4545-8476-4B96182C11CC Q36577661-FD30D3E9-867B-4AED-9A5A-366A44563519 Q36736494-CD37ED74-BB5E-4D39-928C-940AD0317087 Q36766221-4DD03E78-D94A-4D03-ABD2-641D55EE9F04 Q36880864-C3241541-3E91-416C-B9F9-98C540B2ECE9 Q36905620-F91EBA45-3A14-4800-9826-BF099C3F4A3F Q37025981-1A5782C9-A5A6-4CDE-B00E-01AEFDCD37CC Q37150014-9E7E0FF1-9C80-4556-AB1F-639862C49149 Q37989418-C20661CB-1FAD-423E-827A-18566B8B62D3 Q37991223-B432141F-8F0B-4AB3-BED9-40C5B14ADF37 Q38161964-A521D42E-B9C2-4B79-8931-224BB68B8D68 Q38177768-CD385C25-6D2C-48E0-9E1D-0C37ED98A4FD Q38265982-E5306E54-51C2-43A0-879A-BF1180BF6602 Q38698520-A7D362A3-20AB-41DE-9AFA-17704B9C35EB Q38813874-E2CBA4FB-6E99-4770-A494-519F3FF3B80A Q39484798-849C3173-918A-482C-BE02-EA224948761D Q43156043-1B2EFE05-94C1-491A-9EA6-9DC434673E15 Q43811918-59F89437-CC92-44CC-9FD3-BCB0F110BA75 Q44774546-7F7EF560-94F7-4C8A-84F4-7CA874CCC701 Q45720889-08359A8A-AD98-47A3-B3EB-BDD89F10C6CF Q47929120-C31B9420-E9F9-4B51-97EF-4864616BA545 Q48146200-D9439A87-228C-41F7-8276-8E67E66338A6 Q48299846-7D12A9E7-8497-43AA-AEAD-94EBE39B94FC Q50094239-8D743F5D-44C1-469E-9745-D0ABF9D76DF2 Q51072279-2EF14E44-19A4-48DC-A875-52CE643D57B5 Q51562409-EA28D300-B8D7-41D5-91E5-B52516C67554 Q52893458-7F70C177-7E29-4596-B5FC-4991A0952651 Q54274111-EE4FDCAD-6372-45BB-8188-BC6E500F2763 Q54354157-F1137269-1261-415D-B8BE-03CA73A3DECD Q54491280-724E4771-D36F-4B2A-B82D-BBCF0427D206 Q55034870-B7305857-5333-48C4-92AA-01DA1CD688F7 Q58633992-7C1E5E97-BA70-483C-9FC0-AD8DC5155ED3

P2860

Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.

http://www.wikidata.org/entity/Q34185893

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@ast

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@en

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@nl

type

label

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@ast

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@en

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@nl

prefLabel

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@ast

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@en

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@nl

P1433

Q34185893-AB81BFF4-2F1A-489A-8237-678CC2FAD101

P1476

Q34185893-7D631460-B144-42FE-83E8-3A8BD00143EE

P2093

Q34185893-034635E7-74BD-4315-9F33-528C74E28F9B

Q34185893-0482C3C4-0F47-44A5-994E-0F0FAFB48717

Q34185893-0F4C736B-A59F-45B2-AA90-588DA8D319BD

Q34185893-38E4E2A2-FBBA-4890-9B04-BDBE3F24F52B

Q34185893-3F9974D9-E11F-4655-A995-D85C4C237F00

Q34185893-63016FB2-9E84-4230-B321-6B844A63E166

Q34185893-64882628-292E-4B19-A1E6-C9A20951C784

Q34185893-8D24FB4C-2F3C-4696-BE1B-257D540978B1

Q34185893-A5CFF5C4-EC87-41AE-9DEF-9EB1A64EE7F9

Q34185893-B6E0B9F0-1B7E-4422-8F97-E9B1AAB10233

P304

Q34185893-DC249F09-EA7B-436F-9BB4-D5652D73DB80

P31

Q34185893-F479FA42-BEB0-49D7-AB0B-191D3F741DD4

P356

Q34185893-59A829DB-3218-4869-B4FC-46336D35A6B8

P407

Q34185893-4DE8185E-5017-4D08-A359-7A842986D664

P433

Q34185893-D6CB179A-8139-46C4-9051-F21A064C3702

P478

Q34185893-FBFD4A72-109C-454D-B091-34FA310CCC84

P577

Q34185893-B168F390-8486-49CE-83D7-5DEF5FAC601B

P5875

Q34185893-2358E880-EF55-41E0-8ADE-5A2FB2C4CDA4

P698

Q34185893-58302519-4767-476A-9E33-5AD3F9E816DA

P921

Q34185893-6DA3F857-8E9B-47BF-943D-A60FDB177E30

Q34185893-9A2812A2-B6FE-4FE1-ADCF-45055D83A6C3

P356

J.JPEDS.2011.03.046

P1433

The Journal of Pediatrics

P1476

Distinct impact of imatinib on ...... with chronic myeloid leukemia.

@en

P2093

Akihiko Tanizawa

http://www.w3.org/2001/XMLSchema#string

Akihiro Watanabe

http://www.w3.org/2001/XMLSchema#string

Chikako Tono

http://www.w3.org/2001/XMLSchema#string

Haruko Shima

http://www.w3.org/2001/XMLSchema#string

Hideki Muramatsu

http://www.w3.org/2001/XMLSchema#string

Hidemitsu Kurosawa

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Shimada

http://www.w3.org/2001/XMLSchema#string

Kazuko Hamamoto

http://www.w3.org/2001/XMLSchema#string

Keizo Horibe

http://www.w3.org/2001/XMLSchema#string

Koji Kato

http://www.w3.org/2001/XMLSchema#string

P304

676-681

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JPEDS.2011.03.046

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

159

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51146551

http://www.w3.org/2001/XMLSchema#string

P698

21592517

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia